Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narlumosbart vs Denosumab in Multiple Myeloma Bone Disease
NCT06314698Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of narlumosbart in multiple myeloma (MM), sponsored by Renji Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
narlumosbart
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06314698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06314698.